Detection of human cytomegalovirus in bronchoalveolar lavage of intensive care unit patients

Andrea Vergara; Catia Cilloniz; Nestor Luque; Carolina Garcia-Vidal; Javier Tejero; Rafael Perelló; Carmen María Lucena; Antoni Torres; María Angeles Marcos

doi:10.1183/13993003.01332-2017

Tables

TABLE 1

Baseline characteristics, conditions and clinical outcomes, and their associated cytomegalovirus (CMV) PCR results in bronchoalveolar lavage

Variable	Negative CMV (n=98)	Positive CMV (n=35)	p-value
Demographic
Age years (median (IQR))	62.0 (23.0)	61.0 (24.0)	0.37
Men	63 (64)	23 (66)	0.88
Current smoker	31 (36)	7 (25)	0.28
Current alcohol consumer	8 (10)	2 (7)	>0.99
Immunocompromised^#	47 (48)	25 (71)	0.017
HIV	8 (8)	3 (9)	>0.99
Transplant	19 (19)	9 (26)	0.43
Cancer	16 (16)	7 (20)	0.62
Systemic corticosteroids^¶	21 (21)	17 (49)	0.002
Diagnosis at ICU admission			0.73
Respiratory failure	59 (60)	24 (69)
Septic shock	18 (18)	5 (14)
Cardiac failure	9 (9)	2 (6)
Sepsis	5 (5)	1 (3)
Other	7 (7)	3 (9)
Previous antibiotic	7 (7)	3 (9)	0.72
Comorbidities⁺	76 (78)	26 (74)	0.70
Chronic respiratory disease	27 (28)	8 (23)	0.55
Chronic cardiovascular disease	23 (24)	6 (17)	0.44
Diabetes mellitus	12 (12)	6 (17)	0.57
Neurological disease	11 (11)	7 (20)	0.25
Chronic renal disease	12 (12)	7 (20)	0.27
Chronic liver disease	4 (4)	2 (6)	0.65
Arterial hypertension	38 (39)	18 (51)	0.19
Laboratory tests (median (IQR))
Creatinine mg·mL⁻¹	1.0 (1.0)	1.2 (1.1)	0.98
C-reactive protein mg·dL⁻¹	12.5 (15.9)	11.9 (20.0)	0.87
White blood-cell count 10⁹·L⁻¹	10.0 (9.0)	9.0 (12.0)	0.41
SOFA score at ICU admission (median (IQR))	5 (6)	5 (5)	0.91
Outcomes
Pulmonary complications	16 (39)	5 (33)	0.70
NIMV	59 (94)	17 (94)	>0.99
IMV	72 (92)	26 (93)	>0.99
Hospital stay days (median (IQR))	35.0 (33.0)	46.0 (62.0)	0.017
ICU stay days (median (IQR))	19.5 (21.5)	31.5 (69.0)	0.070
30-day mortality	38 (41)	21 (64)	0.024

Data are presented as n (%) unless otherwise stated. Values in bold are for when p<0.05. IQR: interquartile range; ICU: intensive care unit; SOFA: sepsis-related organ failure assessment; NIMV: noninvasive mechanical ventilation; IMV: invasive mechanical ventilation. ^#: subjects may have more than one immunocompromising condition; ^¶: daily doses >20 mg prednisolone-equivalent for more than 2 weeks in the month previous to admission; ⁺: subjects may have more than one comorbid condition.